Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

(2022) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

(2022) Yuqin Song et al.   BLOOD

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

(2022) Michael D. Jain et al.   BLOOD

Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center

(2022) Alexander D. Heini et al.   BONE MARROW TRANSPLANTATION

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

(2022) Gloria Iacoboni et al.   Blood Advances

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

(2022) Michael Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

(2021) Preetesh Jain et al.   AMERICAN JOURNAL OF HEMATOLOGY

Early Relapse Identifies MCL patients with Inferior Survival after Intensive or Less Intensive Frontline Therapy

(2021) David A Bond et al.   Blood Advances

Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel

(2021) Jason T. Romancik et al.   BLOOD

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

(2021) Charles Herbaux et al.   BLOOD

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

(2021) Roni Shouval et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

(2020) Yuqin Song et al.   CLINICAL CANCER RESEARCH

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management

(2020) Preetesh Jain et al.   JOURNAL OF CLINICAL ONCOLOGY

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

(2019) Johannes Duell et al.   JOURNAL OF IMMUNOTHERAPY

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

(2019) Michael Wang et al.   LEUKEMIA

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy

(2018) I. Brian Greenwell et al.   CANCER

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

(2018) Michael Wang et al.   LANCET

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

(2018) Preetesh Jain et al.   BRITISH JOURNAL OF HAEMATOLOGY

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

(2018) Martin Dreyling et al.   BLOOD

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

(2018) Carlo Visco et al.   BRITISH JOURNAL OF HAEMATOLOGY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Postibrutinib outcomes in patients with mantle cell lymphoma

(2016) P. Martin et al.   BLOOD

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

(2016) Eva Hoster et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

(2014) Eva Hoster et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

(2013) Clémentine Sarkozy et al.   GENES CHROMOSOMES & CANCER

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

(2011) A M Halldórsdóttir et al.   LEUKEMIA

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD